Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 – China’s First Broad-Spectrum β-Lactamase Inhibitor for Drug-Resistant Pneumonia

Fineline Cube May 7, 2026
Company Drug

Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China

Fineline Cube May 7, 2026
Company Deals

CMS Plans Secondary Listing on Singapore Exchange to Enhance Shareholder Base and Liquidity

Fineline Cube Jun 25, 2025

China Medical System Holdings Ltd (CMS; HKG: 0867) announced its proposal for a secondary listing...

Company Drug

Livzon’s YJH-012 siRNA Drug Gets NMPA Green Light for Gout Trials

Fineline Cube Jun 25, 2025

China-based Livzon Pharmaceutical Group Inc., (HKG: 1513) announced that its Category 1 chemical drug YJH-012...

Company Medical Device

GE Healthcare Wins FDA Approval for Vizamyl Label Update in Alzheimer’s Detection

Fineline Cube Jun 25, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...

Policy / Regulatory

NHSA Emphasizes Management of Designated Medical Institutions for Healthcare Quality

Fineline Cube Jun 25, 2025

The National Healthcare Security Administration (NHSA) this week released a notification emphasizing the importance of...

Company Deals

Suzhou Porton Biologics Partners with Future Biotechnology to Expand Viral Vector Services

Fineline Cube Jun 25, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd announced this week a...

Company Drug

Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia

Fineline Cube Jun 25, 2025

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations...

Company Drug

Henlius Biotech Doses First Patient in Japanese Bridging Trial of Serplulimab for ES-SCLC

Fineline Cube Jun 25, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced the successful completion of first patient dosing...

Company Drug

C.Q. Pharma’s Prasugrel Clinical Filing Accepted by China’s NMPA

Fineline Cube Jun 25, 2025

China-based C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950) announced that its clinical application for prasugrel...

Company Drug

BeOne Medicines Launches Ziihera for HER2-High Biliary Tract Cancer in China

Fineline Cube Jun 25, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced the official commercial availability...

Company Deals

TINGSN Technology Secures RMB 100M in Series B+ Round for 4D Intracardiac Ultrasound R&D

Fineline Cube Jun 25, 2025

China-based TINGSN Technology has reportedly secured RMB 100 million (USD 14 million) in a Series...

Company Deals

Bayer and Tsinghua University Renew Strategic Research Pact for Drug Innovation

Fineline Cube Jun 25, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and Tsinghua University announced the signing of their...

Company Medical Device

Dynamiker Bio’s Aspergillus Detection Kit Wins NMPA Marketing Approval

Fineline Cube Jun 25, 2025

China-based Dynamiker Biotechnology (Tianjin) Co., Ltd. announced that it has received marketing approval from the...

Company Drug

GSK Gains FDA Clearance for Benlysta Autoinjector in Pediatric Lupus Nephritis

Fineline Cube Jun 25, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that it has received clearance from the US Food...

Company Drug

Medilink Therapeutics’ YL201 Wins FDA Breakthrough Therapy Designation for SCLC

Fineline Cube Jun 25, 2025

Suzhou-based Medilink Therapeutics announced that it has received Breakthrough Therapy Designation (BTD) from the US...

Company Deals Hospital Medical Device

Siemens Healthineers Collaborates with MGH to Advance Theranostics Applications

Fineline Cube Jun 25, 2025

Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant, has entered into a research...

Company Drug

FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC

Fineline Cube Jun 25, 2025

The US Food and Drug Administration (FDA) this week approved Datopotamab deruxtecan (Dato-DXd), a TROP-2-targeted...

Company Drug

TransThera Sciences’ Tinengotinib Gains FDA Fast Track for mCRPC Treatment

Fineline Cube Jun 25, 2025

China-headquartered TransThera Sciences (Nanjing) Inc., (HKG: 2617), which listed in Hong Kong this week, announced...

Company Deals Drug

XtalPi Signs LOI With DoveTree for AI-Powered Drug Development

Fineline Cube Jun 25, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), announced the signing of a Letter...

Company Drug

Merck’s Prevymis Approved in China for Pediatric CMV Prevention

Fineline Cube Jun 25, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that its novel non-nucleoside...

Company Drug

Sansure Biotech Wins NMPA Approval for Fungal Infection Detection Kit

Fineline Cube Jun 24, 2025

China’s National Medical Products Administration (NMPA) has approved Sansure Biotech Inc.’s (SHA: 688289) Pneumocystis jirovecii,...

Posts pagination

1 … 132 133 134 … 660

Recent updates

  • Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 – China’s First Broad-Spectrum β-Lactamase Inhibitor for Drug-Resistant Pneumonia
  • Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China
  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 – China’s First Broad-Spectrum β-Lactamase Inhibitor for Drug-Resistant Pneumonia

Company Drug

Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.